Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
With
UCB Pharma
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Skeletally mature adults, age 18 to 85 years with radiographically closed growth plates
Fresh unilateral closed or Gustilo type I or type II open tibial fracture
Definitive fracture fixation with reamed (closed and open fractures) or unreamed (open fractures only) intramedullary nailing
You may not be if
Major polytrauma or significant axial trauma
Associated lower extremity fracture that will delay subject's ability to bear weight beyond the normal time expected for a tibial shaft fracture
Use of bone grafts at the time of fracture fixation
Pathological fracture or metabolic or bone disease
History of symptomatic spinal stenosis or facial nerve paralysis
Malignancy within the last 5 years
Evidence of the following (currently or within the past 5 years): elevated transaminases, significantly impaired renal function, current hyper- or hypocalcaemia
Use of agents affecting bone metabolism
Subject refuses to use appropriate methods of contraception
Clareo Health | Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
